NCT01327612 2021-02-21
Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
Amgen
Phase 2 Completed
Clinical Trials
11 trialsNCT01492673 2019-10-29
Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00643565 2019-10-22
A Study of Avastin (Bevacizumab) in Combination With Standard Chemotherapy in Children and Adolescents With Sarcoma.
Hoffmann-La Roche
Phase 2 Completed
NCT01661283 2019-03-06
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Sarcoma Alliance for Research through Collaboration
Phase 2 Completed
NCT01106872 2018-08-10
Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas
University of Iowa
Phase 1 Completed
NCT00288015 2018-06-25
Bevacizumab in Treating Patients With Angiosarcoma
Northwestern University
Phase 2 Completed
NCT00356031 2017-05-19
Bevacizumab and Radiation Therapy for Sarcomas
Massachusetts General Hospital
Phase 2 Completed
NCT01222715 2017-05-05
Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00887809 2016-01-25
Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00276055 2015-06-19
Phase IB Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft Tissue Sarcoma
New Mexico Cancer Research Alliance
Phase 1 Completed
NCT00052390 2013-06-24
Doxorubicin and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 2 Completed